week 19 check-in — 9kg down, early fullness manageable, one thing confusing me
week 19 check-in — 9kg down, early fullness manageable, one thing confusing me, logged the same way every week so the comparison is at least internally fair.
The numbers the title promised, since a headline without them is worthless: week 19 and 9kg. Everything below is context for those.
Kept a log specifically because there is so little published. It is one person and it is not data.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
What is the source for that figure — the published paper or a summary of it?
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
What do you think the glucagon component is adding, specifically?
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Nothing containing this compound is approved anywhere.
ewan_zielinski is right about the escalation being the variable. It explains most of the difficult reports here.
Nothing containing this compound is approved anywhere.
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
How fast was the escalation? That is usually the variable that explains the reports.
Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.
This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.
dose escalation in the trials was slow for a reason
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
Are you comparing against phase 3 numbers for something else? They are not comparable.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Are you tracking heart rate at all?
a lot of the confident posting here is extrapolation
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
small trial, big effect, wide error bars
- 1Standing reminder in every thread here: unapproved compound, research…7 comments in this branch · started by u/incretin_ivy
- 2Increases in heart rate have been reported across this receptor class. The…7 comments in this branch · started by u/zeynep_mbeki